Home > Haematology > Venetoclax boosts progression-free survival in myeloma patients, but may cause more deaths

Venetoclax boosts progression-free survival in myeloma patients, but may cause more deaths

Journal
Lancet Oncology
Reuters Health - 11/11/2020 - The oral BCL-2 inhibitor venetoclax prolongs progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (MM), but at the cost of lower overall survival, a phase-3 trial suggests. In subset analyses, however, patients with translocation t(11;14) and high BCL-2 expression appeared to reap the PFS benefit without increased mortality, researchers report in The Lancet Oncology. "Addition of venetoclax to bortezomib and dexamethasone appears to improve the progression free survival and depth of response in relapsed myeloma," lead author Dr. Shaji K. Kumar of the Mayo Clinic in Rochester, Minnesota, the study's first author, told Reuters Health by email. "The benefit appears to be mostly in the t(11;14) subgroup of patients." Between 15% and 20% of multiple myeloma patients have t(11;14), Dr. Kumar noted. Venetoclax (VENCLEXTA, Abbvie and Genentech) has been approved by the U.S. Food and Drug Adminis...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on